Refine
Document Type
- Article (6)
Has Fulltext
- yes (6)
Is part of the Bibliography
- no (6)
Keywords
- Aedes aegypti (1)
- Angioplasty (1)
- Anopheles stephensi (1)
- Biomarkers (1)
- Diagnostic medicine (1)
- Hemodynamics (1)
- Immunology (1)
- Lockstoffe (1)
- Mückenmonitoring (1)
- Natriuretic peptide (1)
Institute
- Medizin (5)
Stechmücken der Art Stegomyia aegypti (ehemals Aedes aegypti, REINERT et al. 2004) sind die wichtigsten Überträger von Gelbfieber- und Dengueviren. Diverse Arten der Gattung Anopheles verbreiten die Erreger der Malaria. Bei Versuchen, Malaria, Gelbfieber und Dengue einzudämmen, wurden in den letzten Jahrzehnten wiederholt Kampagnen gegen Stechmücken geführt. Dabei wurden Insektizide vielfach flächendeckend ausgebracht. Dies führte kurzfristig zu geringeren Mückendichten, allerdings entwickelten sich auch vielerorts gegen diese Gifte resistente Mückenpopulationen. Anstelle des flächendeckenden Gifteinsatzes wird heute versucht, die Insektizide örtlich und zeitlich effektiv einzusetzen, um so die Gefahr weiterer Resistenzbildung zu minimieren und sowohl die Kosten als auch die Belastung für Umwelt und Bevölkerung möglichst gering zu halten. Um Insektizide zur richtigen Zeit gezielt ausbringen zu können, ist ein Monitoring der Mücken erforderlich. Mückenfallen, die durch optische Effekte und Duftstoffe gezielt anthropophile Stechmückenarten anlocken, sind für ein derartiges Bestandsmonitoring besonders geeignet. Auf der Suche nach attraktiven Duftstoffen, welche die Effektivität solcher Fallen erhöhen, wurde unter anderem auch 2-Undecanon getestet. In Verhaltensversuchen mit den anthropophilen Mückenarten Stegomyia aegypti und Anopheles stephensi konnte die Attraktivität dieser Substanz sowohl als Einzelreiz als auch in Kombination mit anderen Attraktanzien gezeigt und quantifiziert werden.
Activated SUMOylation restricts MHC class I antigen presentation to confer immune evasion in cancer
(2022)
Activated SUMOylation is a hallmark of cancer. Starting from a targeted screening for SUMO-regulated immune evasion mechanisms, we identified an evolutionarily conserved function of activated SUMOylation, which attenuated the immunogenicity of tumor cells. Activated SUMOylation allowed cancer cells to evade CD8+ T cell–mediated immunosurveillance by suppressing the MHC class I (MHC-I) antigen-processing and presentation machinery (APM). Loss of the MHC-I APM is a frequent cause of resistance to cancer immunotherapies, and the pharmacological inhibition of SUMOylation (SUMOi) resulted in reduced activity of the transcriptional repressor scaffold attachment factor B (SAFB) and induction of the MHC-I APM. Consequently, SUMOi enhanced the presentation of antigens and the susceptibility of tumor cells to CD8+ T cell–mediated killing. Importantly, SUMOi also triggered the activation of CD8+ T cells and thereby drove a feed-forward loop amplifying the specific antitumor immune response. In summary, we showed that activated SUMOylation allowed tumor cells to evade antitumor immunosurveillance, and we have expanded the understanding of SUMOi as a rational therapeutic strategy for enhancing the efficacy of cancer immunotherapies.
Aims: Balloon pulmonary angioplasty (BPA) is an interventional treatment modality for inoperable chronic thromboembolic pulmonary hypertension (CTEPH). Therapy monitoring, based on non-invasive biomarkers, is a clinical challenge. This post-hoc study aimed to assess dynamics of high-sensitivity cardiac troponin T (hs-cTnT) as a marker for myocardial damage and its relation to N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels as a marker for cardiac wall stress.
Methods and results: This study included 51 consecutive patients who underwent BPA treatment and completed a 6-month follow-up (6-MFU) between 3/2014 and 3/2017. Biomarker measurement was performed consecutively prior to each BPA and at 6-MFU.
In total, the 51 patients underwent an average of 5 BPA procedures. The 6-month survival rate was 96.1%. The baseline (BL) meanPAP (39.5±12.1mmHg) and PVR (515.8±219.2dyn×sec×cm-5) decreased significantly within the 6-MFU (meanPAP: 32.6±12.6mmHg, P<0.001; PVR: 396.9±182.6dyn×sec×cm-5, P<0.001). At BL, the median hs-cTnT level was 11 (IQR 6–16) ng/L and the median NT-proBNP level was 820 (IQR 153–1872) ng/L. The levels of both biomarkers decreased steadily after every BPA, showing the first significant difference after the first procedure. Within the 6-MFU, hs-cTnT levels (7 [IQR 5–12] ng/L; P<0.001) and NT-proBNP levels (159 [IQR 84–464] ng/l; P<0.001) continued to decrease. The hs-cTnT levels correlated with the PVR (rrs = 0.42; p = 0.005), the meanPAP (rrs = 0.32; p = 0.029) and the NT-proBNP (rrs = 0.51; p<0.001) levels at BL.
Conclusion: Non-invasive biomarker measurement provides valuable evidence for the decreasing impairment of myocardial function and structure during BPA therapy. Changes in hs-cTNT levels are suggestive for a reduction in ongoing myocardial damage.
Background: Patients with cancer have an increased risk of VTE. We compared VTE rates and bleeding complications in 1) cancer patients receiving LMWH or UFH and 2) patients with or without cancer.
Patients with cancer have an increased risk of VTE. We compared VTE rates and bleeding complications in 1) cancer patients receiving LMWH or UFH and 2) patients with or without cancer.
Methods: Acutely-ill, non-surgical patients ≥70 years with (n = 274) or without cancer (n = 2,965) received certoparin 3,000 UaXa o.d. or UFH 5,000 IU t.i.d. for 8-20 days.
Results: 1) Thromboembolic events in cancer patients (proximal DVT, symptomatic non-fatal PE and VTE-related death) occurred at 4.50% with certoparin and 6.03% with UFH (OR 0.73; 95% CI 0.23-2.39). Major bleeding was comparable and minor bleedings (0.75 vs. 5.67%) were nominally less frequent. 7.5% of certoparin and 12.8% of UFH treated patients experienced serious adverse events. 2) Thromboembolic event rates were comparable in patients with or without cancer (5.29 vs. 4.13%) as were bleeding complications. All cause death was increased in cancer (OR 2.68; 95%CI 1.22-5.86). 10.2% of patients with and 5.81% of those without cancer experienced serious adverse events (OR 1.85; 95% CI 1.21-2.81).
Conclusions: Certoparin 3,000 UaXa o.d. and 5,000 IU UFH t.i.d. were equally effective and safe with respect to bleeding complications in patients with cancer. There were no statistically significant differences in the risk of thromboembolic events in patients with or without cancer receiving adequate anticoagulation.
Trial Registration: clinicaltrials.gov, NCT00451412